Fingerprint phase: tumor with ≥20% tumor content plus 1–2 ml EDTA blood or 1–2 µg normal DNA. Monitoring phase: 3 × 10 ml cfDNA tubes at each time point.
TUMOR DIAGNOSTICS
CancerMRD
First creates a patient-specific tumor fingerprint from whole-genome tumor–normal analysis, then tracks those variants in serial cfDNA samples.
Whole-genome tumor–normal discovery followed by personalized multiplex cfDNA monitoring; referenced limit of detection down to 0.02% tumor content (200 ppm).
Patient-specific molecular signal over time, with quantitative longitudinal comparison and assay limitations.
Fingerprint design and monitoring timing are confirmed after sample review.
CLINICAL VALUE
Where this test is strongest
✓Personalized tumor fingerprint
✓Whole-genome discovery rather than a fixed hotspot panel
✓Referenced detection down to 0.02% tumor content
✓Designed for serial longitudinal monitoring
LIMITATIONS
What must remain visible
!No fixed gene list: tracked variants are unique to each tumor.
!Not suitable for every tumor; low-shedding cancers can produce false-negative plasma results.
!A baseline tumor and matched normal sample are needed to create the fingerprint.
GENE & ANALYTICAL SCOPE
Personalized; no fixed list
No fixed gene list. Whole-genome tumor–normal analysis selects a personalized set of variants for monitoring.
Personalized WGS fingerprintCase-specific analytical scope+
Tumor-specific variants are selected genome-wide and converted into an individualized cfDNA monitoring assay.
No fixed gene-by-gene list applies to this scope.
BEFORE ORDERING
Confirm the current laboratory specification.
The official case review and quotation confirm eligibility, accepted material, validated coverage and variant classes, consent, turnaround, price, and report pathway.